Motor performance differentiates individuals with Lewy body dementia, Parkinson’s and Alzheimer’s disease

Fritz, Nora; Kegelmeyer, Deborah; Kloos, Anne; Linder, Shannon; Park, Ariane; Kataki, Maria; Adeli, Anahita; Agrawal, Punit; Scharre, Douglas W.; Kostyk, Sandra K.

doi:10.1016/j.gaitpost.2016.08.009

Cited by 79 publications

(66 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DLB patients can develop parkinsonism of increasing severity over the years with prevalence between 60 and 92% , although 18% of neuropathologically confirmed DLB cases never developed . Rest tremor is less frequent in DLB than PDD and in DLB is usually milder and more symmetrical . More severe parkinsonism is associated with PDD ; the PIGD phenotype is more likely to be found in PDD (88%) and DLB (69%) compared to PD (38%) .…”

Section: Methodsmentioning

confidence: 99%

Review: Clinical, neuropathological and genetic features of Lewy body dementias

Hansen

Ling

Lashley

et al. 2019

Neuropathology Appl Neurobio

View full text Add to dashboard Cite

2019) Neuropathology and Applied Neurobiology 45, 635-654 Clinical, neuropathological and genetic features of Lewy body dementias Lewy body dementias are the second most common neurodegenerative dementias after Alzheimer's disease and include dementia with Lewy bodies and Parkinson's disease dementia. They share similar clinical and neuropathological features but differ in the time of dementia and parkinsonism onset. Although Lewy bodies are their main pathological hallmark, several studies have shown the emerging importance of Alzheimer's disease pathology. Clinical amyloid-b imaging using Pittsburgh Compound B (PiB) supports neuropathological studies which found that amyloid-b pathology is more common in dementia with Lewy bodies than in Parkinson's disease dementia. Nevertheless, other co-occurring pathologies, such as cerebral amyloid angiopathy, TDP-43 pathology and synaptic pathology may also influence the development of neurodegeneration and dementia. Recent genetic studies demonstrated an important role of APOE genotype and other genes such as GBA and SNCA which seem to be involved in the pathophysiology of Lewy body dementias. The aim of this article is to review the main clinical, neuropathological and genetic aspects of dementia with Lewy bodies and Parkinson's disease dementia. This is particularly relevant as future management for these two conditions may differ.

show abstract

Section: Methodsmentioning

confidence: 99%

Review: Clinical, neuropathological and genetic features of Lewy body dementias

Hansen

Ling

Lashley

et al. 2019

Neuropathology Appl Neurobio

View full text Add to dashboard Cite

show abstract

“…Quantitative gait analysis included the use of gait walkway systems [17][18][19][20][21][22][23][24][25], accelerometers [26][27][28][29][30], motion capture analysis systems [31][32][33][34][35], pressurized foot-sensors [19,[36][37][38][39] and combinations of these and other methods such as forceplates [40] and digital cameras [41].…”

Section: Measurement Of Gait In Dementiamentioning

confidence: 99%

“…All 26 papers investigated pace , 18 studies described characteristics relating to rhythm [18-20, 23-27, 29, 30, 32-35, 38, 39, 41], 13 studies reported gait variability [17, 19, 24-29, 31-33, 35, 39], two studies described characteristics of gait asymmetry [26,27] and nine reported parameters relating to postural control [17-20, 25, 33, 34, 39, 40, 42]. [17-20, 22-30, 32-36, 38, 40, 42], four studies compared AD to other dementia subtypes [18,25,39,42], four compared AD to MCI [22,[26][27][28] and four studies compared AD severity levels [21,31,36,41].…”

Section: Measurement Of Gait In Dementiamentioning

confidence: 99%

“…In AD, all 25 studies assessed characteristics of pace, such as step velocity, step length, step, stance and swing time variability [17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][38][39][40][41][42] (See table 2 for specific study details). People with AD typically walked with reduced pace [17-20, 22-30, 32-36, 38, 40, 42] compared to controls, and were more impaired in severe AD [32,36].…”

Section: Measurement Of Gait In Dementiamentioning

confidence: 99%

“…All studies assessed characteristics of pace [18,37,39] and generally found reduced pace compared to controls [18,37]. Findings were also inconsistent between LBD and PD, with one study reporting reduced pace in LBD [39] and another study showing no group differences between PDD and PD [37]. No significant differences were found between subtypes of LBD [45].…”

Section: Gait Impairments In Lewy Body Dementiamentioning

confidence: 99%

See 2 more Smart Citations

What Can Quantitative Gait Analysis Tell Us about Dementia and Its Subtypes? A Structured Review

Ardle

Morris

Wilson

et al. 2017

JAD

View full text Add to dashboard Cite

Distinguishing dementia subtypes can be difficult due to similarities in clinical presentation. There is increasing interest in discrete gait characteristics as markers to aid diagnostic algorithms in dementia. This structured review explores the differences in quantitative gait characteristics between dementia and healthy controls, and between four dementia subtypes under single-task conditions: Alzheimer's disease (AD), dementia with Lewy bodies and Parkinson's disease dementia, and vascular dementia. Twenty-six papers out of an initial 5,211 were reviewed and interpreted using a validated model of gait. Dementia was associated with gait characteristics grouped by slower pace, impaired rhythm, and increased variability compared to normal aging. Only four studies compared two or more dementia subtypes. People with AD are less impaired in pace, rhythm, and variability domains of gait compared to non-AD dementias. Results demonstrate the potential of gait as a clinical marker to discriminate between dementia subtypes. Larger studies using a more comprehensive battery of gait characteristics and better characterized dementia sub-types are required.

show abstract

Gait variability across neurodegenerative and cognitive disorders: Results from the Canadian Consortium of Neurodegeneration in Aging (CCNA) and the Gait and Brain Study

Pieruccini‐Faria

Black

Masellis

et al. 2021

Alzheimer's & Dementia

105

View full text Add to dashboard Cite

Introduction Gait impairment is common in neurodegenerative disorders. Specifically, gait variability—the stride‐to‐stride fluctuations in distance and time—has been associated with neurodegeneration and cognitive impairment. However, quantitative comparisons of gait impairments across the cognitive spectrum of dementias have not been systematically investigated. Methods Older adults (N = 500) with subjective cognitive impairment, Parkinson disease (PD), mild cognitive impairment (MCI), PD‐MCI, Alzheimer's disease (AD), PD‐dementia, Lewy body dementia, and frontotemporal dementia, as well cognitive normal controls, who were assessed for their gait and cognitive performance. Results Factor analyses grouped 11 quantitative gait parameters and identified four independent gait domains: rhythm, pace, variability, and postural control, for group comparisons and classification analysis. Among these domains, only high gait variability was associated with lower cognitive performance and accurately discriminated AD from other neurodegenerative and cognitive conditions. Discussion Our findings indicate that high gait variability is a marker of cognitive‐cortical dysfunction, which can help to identify Alzheimer's disease dementia.

show abstract

Motor performance differentiates individuals with Lewy body dementia, Parkinson’s and Alzheimer’s disease

Cited by 79 publications

References 29 publications

Review: Clinical, neuropathological and genetic features of Lewy body dementias

Review: Clinical, neuropathological and genetic features of Lewy body dementias

What Can Quantitative Gait Analysis Tell Us about Dementia and Its Subtypes? A Structured Review

Gait variability across neurodegenerative and cognitive disorders: Results from the Canadian Consortium of Neurodegeneration in Aging (CCNA) and the Gait and Brain Study

Contact Info

Product

Resources

About